The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.
Achinger-Kawecka J, Stirzaker C, Portman N, Campbell E, Chia KM, Du Q, Laven-Law G, Nair SS, Yong A, Wilkinson A, Clifton S, Milioli HH, Alexandrou S, Caldon CE, Song J, Khoury A, Meyer B, Chen W, Pidsley R, Qu W, Gee JMW, Schmitt A, Wong ES, Hickey TE, Lim E, Clark SJ.
Achinger-Kawecka J, et al. Among authors: qu w.
Nat Struct Mol Biol. 2024 Mar;31(3):498-512. doi: 10.1038/s41594-023-01181-7. Epub 2024 Jan 5.
Nat Struct Mol Biol. 2024.
PMID: 38182927
Free PMC article.
Significant DNA hypomethylation associates with ectopic activation of ER-enhancers, gain in ER binding, creation of new 3D enhancer-promoter interactions and concordant up-regulation of ER-mediated transcription pathways. Importantly, long-term withdrawal of epigenetic the …
Significant DNA hypomethylation associates with ectopic activation of ER-enhancers, gain in ER binding, creation of new 3D enhancer-promoter …